AAA
AVBP icon

Affinity Asset Advisors’s ArriVent BioPharma AVBP Stock Holding History

Affinity Asset Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.04M Buy
175,000
+25,000
+17% +$565K 0.21% 80
2025
Q4 		$3.02M Buy
+150,000
New +$3.12M 0.17% 74

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Affinity Asset Advisors's AVBP Position: Q1 2026 in Review

Affinity Asset Advisors increased its ArriVent BioPharma (AVBP) stake by 17% in Q1 2026, buying an estimated $565K and bringing the position to 175,000 shares worth $4.04M. The position accounts for 0.21% of the portfolio, ranked #80.

Affinity Asset Advisors first reported a position in AVBP in Q4 2025 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Affinity Asset Advisors held 175,000 shares of ArriVent BioPharma worth $4.04M as of Q1 2026.
  • Affinity Asset Advisors bought 25,000 ArriVent BioPharma shares in Q1 2026, an estimated $565K.
  • ArriVent BioPharma made up 0.21% of Affinity Asset Advisors's portfolio in Q1 2026, its #80 holding.
  • Affinity Asset Advisors first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.